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Introduction {#sec005}
============

The effect of menopausal hormone therapy (MHT), previously known as hormone replacement therapy, on cardiovascular health in post-menopausal women remains controversial and unclear. Extensive observational data had suggested MHT to be cardioprotective \[[@pone.0194015.ref001]--[@pone.0194015.ref003]\], leading to MHT being routinely prescribed for both primary and secondary prevention of coronary heart disease (CHD). However, subsequent data from the Women's Health Initiative (WHI) and Heart and Estrogen/Progestin Replacement Study (HERS) studies cast doubt on the beneficial cardiovascular effects of MHT \[[@pone.0194015.ref004]--[@pone.0194015.ref006]\]; this was reflected in learned societies' clinical guidance concerning MHT's role in CHD prevention \[[@pone.0194015.ref007],[@pone.0194015.ref008]\]. The most recent randomised trial data on the subject arose from the Danish Osteoporosis Prevention Study \[[@pone.0194015.ref009]\], which indicated that women taking MHT had a reduced risk of the composite endpoint of mortality, heart failure and myocardial infarction but the study has been subject to criticism \[[@pone.0194015.ref010]\]. In more recent work, again from the WHI, there was no difference in cardiovascular mortality in MHT users compared to placebo, although the authors themselves state that cause-specific mortality data should be interpreted "cautiously" \[[@pone.0194015.ref011]\]. it has been suggested that commencement of MHT in the perimenopausal transition or early menopause is not associated with increased risk of CHD compared to when treatment is administered at a later stage. This is known as the "timing hypothesis" \[[@pone.0194015.ref012],[@pone.0194015.ref013]\].

The UK Biobank is an ongoing, large-scale, population-based study designed to examine determinants of health in middle and old age \[[@pone.0194015.ref014]\]. Besides extensive collection of health questionnaire data, biological samples and physical measurements, it has incorporated cardiovascular magnetic resonance (CMR) imaging--the gold standard for analysis of cardiac structure and function--to provide detailed imaging phenotypes \[[@pone.0194015.ref015]\]. At present, there is a paucity of data on the effects of MHT on left ventricular (LV) and left atrial (LA) volumes and function, alterations in which are markers of subclinical cardiovascular disease and have prognostic implications.

This cross-sectional study aims to examine the impact of MHT on left ventricular and left atrial structure and function, as assessed by CMR, in a large, population-based cohort.

Methods {#sec006}
=======

Study population {#sec007}
----------------

The UK Biobank is a versatile scientific resource, in which questionnaire data, physical measurements and biological samples were collected from over 500,000 individuals aged 40--69 between 2006 and 2010 registered with the UK National Health Service; the study protocol has been described in detail previously \[[@pone.0194015.ref014]\]. Additionally, the UK Biobank imaging enhancement study is ongoing with the aim of performing, in a single visit, brain, heart, whole body, carotid artery, bone and joint imaging in 100,000 of the original 500,000 participants. Cardiovascular magnetic resonance imaging (CMR) was selected as the modality of choice for heart imaging. The study population presented here consists of 1604 individuals, a subset of the 5,065 individuals who underwent CMR examination as part of the pilot phase (April 2014 --August 2015) of the UK Biobank imaging enhancement. All participants provided written consent; UK Biobank's scientific protocol and operational procedures were reviewed and approved by the North West Multi-centre Research Ethics Committee in the UK \[[@pone.0194015.ref014]\]. The research presented here was conducted under access application 2964 and was approved by the UK Biobank access committee.

Exclusion criteria {#sec008}
------------------

Male participants (n = 2356), female participants not reporting having undergone menopause (n = 693), participants reporting myocardial infarction, angina, heart failure, arrhythmias (including atrial fibrillation), cardiomyopathy, stroke or peripheral vascular disease (n = 76), and participants using MHT for \< 3 years or with missing duration data (n = 246) were excluded from the analysis leaving a study population of 1604.

CMR protocol and image analysis {#sec009}
-------------------------------

The UK Biobank CMR protocol has been described in detail elsewhere \[[@pone.0194015.ref016]\]. Briefly, all examinations were performed on a wide-bore 1.5 Tesla scanner (MAGNETOM Aera, Syngo Platform VD13A, Siemens Healthcare, Erlangen, Germany). For cardiac function, long axis cines and a complete short axis stack of balanced steady-state free precession (bSSFP) cines, covering the left and right ventricle were acquired.

Analysis of the cardiac chambers for all CMR examinations was performed manually across two core laboratories according to pre-approved standard operating procedures using cvi^42^ post-processing software (Version 5.1.1, Circle Cardiovascular Imaging Inc., Calgary, Canada) by observers blinded to all exposures. LV papillary muscles were included in blood pool volumes and excluded from LV mass. Detailed descriptions of analysis methodology, including reference ranges, exemplar contours and intra- and inter-observer variability, have been previously described \[[@pone.0194015.ref017]\]. The CMR parameters examined in this study were left ventricular end-diastolic volume, end-systolic volume, stroke volume, ejection fraction and mass and left atrial maximal volume.

Hormone replacement therapy and menopause {#sec010}
-----------------------------------------

To reliably assess the impact of MHT on cardiac structure and function, only women using MHT for ≥ 3 years were included in the analysis. Data concerning MHT use was derived from UK Biobank fields 3546 (age last used MHT) and 3536 (age started MHT). Duration of MHT use was calculated by subtracting values in these two fields. Where women indicated that they were still currently using MHT, age at the time of imaging visit was used to determine duration. Duration of menopause was calculated by subtracting age at menopause (data field 3581) from age at time of imaging visit. To assess the impact of the "timing hypothesis", a timing variable was created defined as age of menopause subtracted from age started MHT expressed in years.

Statistical analyses {#sec011}
--------------------

Descriptive statistics for continuous variables were presented as mean ± standard deviation or median and interquartile range (IQR) whilst categorical variables were presented as number (percentage). Differences in means were tested using unpaired t-test or Mann-Whitney-U test and differences in percentages using chi-squared test. CMR parameters used as dependent variables were LV end-diastolic volume, LV end-systolic volume, LV stroke volume, LV ejection fraction, LV mass, and LA maximal volume. All dependent variables were assessed for normality using histograms and quantile-quantile plots; natural logarithmic transformation was performed for all dependent variables barring LV ejection fraction. For each dependent variable, outliers were defined as measurements more than three interquartile ranges below the first quartile or above the third quartile and removed from analysis. With respect to missing values, the data presented is a complete case analysis.

To examine the impact of MHT use on cardiac structure and function, multivariable linear regression models were fitted for each cardiac (dependent) variable. With our sample size, the study has 80% power at the 5% significance level to detect a 0.15 standard deviation difference in any of the continuous variables; this would be considered a small effect size \[[@pone.0194015.ref018]\]. Co-variates included in the model (Model 1) were age, age at menopause, ethnicity, height, weight, systolic blood pressure, diastolic blood pressure, smoking status, regular alcohol use, presence of raised cholesterol, presence of diabetes, Townsend deprivation index and income. Height and weight were included as covariates in the model rather than indexing the dependent variables, as the use of ratios in regression analysis can lead to spurious results and misinterpretation \[[@pone.0194015.ref019],[@pone.0194015.ref020]\]. The adjustment made ensured all variables in the model were appropriately adjusted for body composition. The variance inflation factor was calculated to test for multicollinearity. Where cardiac variables had been log-transformed, the beta coefficients were anti-logged and expressed as a percentage difference.

To determine whether the effect of MHT use on each of the cardiac outcomes differed by age, multivariable regression models were constructed with a cross-product of age and MHT fitted as an interaction term. Co-variates included: duration of MHT use fitted as thirds, ethnicity, height, weight, systolic blood pressure, diastolic blood pressure, smoking status, regular alcohol use, presence of raised cholesterol, presence of diabetes, Townsend deprivation index and income (Model 2). Interactions were tested using age as a continuous variable. For ease of interpretation we also fitted the interaction using tertile of age and presented effect sizes for MHT use by tertile.

The effect of multiple testing was considered by determining false discovery rates using the Benjamini--Yekutieli procedure in order to establish the proportion of the rejected hypotheses that are likely to be true positives.

In sensitivity analyses, to examine differences between the MHT use ≥ 3 years and no MHT use groups on CMR parameters, propensity-score matching was used. Matching was performed using all co-variates used in Model 1 at a one-to-one ratio. Differences between MHT use ≥ 3 years and propensity-matched controls was assessed using paired t-test.

To examine the effect of missing data, multiple imputation by chained equations was used to impute 20 complete datasets on which the analysis was repeated and the results pooled. Predictive mean matching with five nearest neighbours was used for continuous variables and logistic regression for binary variables. Plots were examined to assess convergence and plausibility of estimates.

All statistical analyses were performed using R (version 3.3.2) \[[@pone.0194015.ref021]\].

Results {#sec012}
=======

A total of 1,604 participants were included in this study, 513 post-menopausal women who had used MHT for ≥ 3 years and 1,091 post-menopausal women who had never used MHT; case selection is depicted in [Fig 1](#pone.0194015.g001){ref-type="fig"}. The mean number of outliers for CMR variables was 2 (range = 0--7).

![Case selection flowchart.](pone.0194015.g001){#pone.0194015.g001}

Baseline characteristics for the study population, divided by never used MHT vs MHT use ≥ 3 years, are presented in [Table 1](#pone.0194015.t001){ref-type="table"}. The mean age (65.4±5.7 vs 61.3±6.4; P\<0.0001) was higher and the median age at menopause (50 \[IQR = 45--52\] vs 51 \[IQR = 48--53\]; p\<0.0001) was lower in the MHT cohort compared to the never used MHT cohort. For those using MHT, the median number of years of MHT use was 8 (IQR = 5--11) and the mean age of commencement was 47.6±5.3. At the time of CMR examination, 15.2% (n = 78) were still on treatment. There was no significant difference in socioeconomic status measures between MHT users and non-users including Townsend deprivation index, household income or educational attainment.

10.1371/journal.pone.0194015.t001

###### Baseline characteristics.

![](pone.0194015.t001){#pone.0194015.t001g}

                                        Never used MHT   MHT use ≥ 3 years
  ------------------------------------- ---------------- -------------------
  **Age, years**                        61.3 (6.4)       65.4 (5.7)
  **BMI, kg/m**^**2**^                  26.0 (4.7)       25.9 (4.3)
  **Ethnicity (% Caucasian)**           92% (1004)       93% (475)
  **Height, cm**                        163 (6.2)        162 (6.1)
  **SBP, mmHg**                         133 (18.8)       135 (19.3)
  **DBP, mmHg**                         77 (9.9)         76 (10.0)
  **Hypercholesterolaemia**             11.9% (130)      19.5% (100)
  **Diabetes**                          3.7% (40)        4.1% (21)
  **Current smoker**                    2.8% (31)        3.7% (19)
  **Regular alcohol**                   16.6% (154)      22.9% (103)
  **Mean age at menopause (years)**     50.6 (4.3)       48.3 (6.4)
  **Median age at menopause (years)**   51 \[48--53\]    50 \[45--52\]
  **Mean age commenced MHT (years)**    N/A              47.6 (5.3)
  **Median duration of MHT (years)**    N/A              8 \[5--11\]

\*Indicates data presented as median (interquartile range)

Mean CMR parameters for each cohort are presented in [Table 2](#pone.0194015.t002){ref-type="table"}. Before adjustment, women who had used MHT ≥ 3 years had significantly smaller LV end-diastolic volume (117±22 ml vs 124±22 ml; p\<0.0001), LV end-systolic volume (46±12 ml vs 48±12 ml; p \<0.005), LV stroke volume (71±14 ml vs 75±14 ml; p\<0.0001) and LA maximal volume (57±17 ml vs 61±17 ml; p\<0.0001) compared to the cohort who had never used MHT. There was no significant difference in LV mass between the two groups.

10.1371/journal.pone.0194015.t002

###### Mean CMR parameters, unadjusted.

![](pone.0194015.t002){#pone.0194015.t002g}

                                Never used MHT   MHT use ≥ 3 years   P value
  ----------------------------- ---------------- ------------------- ----------
  **LV end-diastolic volume**   123.7 (21.4)     117.6 (21.6)        \<0.0001
  **LV end-systolic volume**    47.9 (12.0)      45.8 (11.9)         0.002
  **LV stroke volume**          74.9 (13.6)      70.7 (14.2)         \<0.0001
  **LV ejection fraction**      60.9 (5.7)       60.5 (6.2)          0.313
  **LV mass**                   72.1 (13.7)      71.3 (14.1)         0.325
  **LA maximal volume**         60.9 (17.2)      56.9 (16.8)         \<0.0001

The effect of MHT use on LV and LA CMR parameters in fully adjusted models is detailed in [Table 3](#pone.0194015.t003){ref-type="table"}. Use of MHT for ≥ 3 years was associated with a significant reduction in LV end-diastolic volume (123 ml vs 120 ml, effect size = -2.4%, 95% confidence interval \[CI\]: -4.2% to -0.5%; p = 0.013), LV stroke volume (74 ml vs 72 ml, effect size = -3.1%, 95% CI: -5.1% to -1.0%; p = 0.004) and LA maximal volume (60 ml vs 58 ml, effect size = -4.5%, 95% CI: -7.8% to -1.0%; p = 0.012). These associations remained significant at a false discovery rate of 10%. To further examine these associations produced by complete case analysis, multiple imputation of missing values was performed and the analysis repeated. The same CMR variables demonstrated significant associations with MHT use; these results are detailed in [S1 Table](#pone.0194015.s001){ref-type="supplementary-material"}.

10.1371/journal.pone.0194015.t003

###### Effect of MHT use ≥ 3 years on CMR parameters in fully-adjusted models.

![](pone.0194015.t003){#pone.0194015.t003g}

                                Adjusted mean: never used MHT   Adjusted mean: MHT use \> = 3 years   Effect size (%)   95% Confidence Interval   p value
  ----------------------------- ------------------------------- ------------------------------------- ----------------- ------------------------- ---------
  **LV end-diastolic volume**   122.8                           119.8                                 -2.4              (-4.2, -0.5)              0.013
  **LV end-systolic volume**    47.5                            46.9                                  -1.3              (-4.2,1.6)                0.383
  **LV stroke volume**          74.3                            72.1                                  -3.1              (-5.1, -1.0)              0.004
  **LV ejection fraction**      60.9                            60.4                                  -0.5              (-1.2, 0.3)               0.212
  **LV mass**                   71.5                            71.6                                  0.1               (-1.9, 2.2)               0.914
  **LA maximal volume**         60.2                            57.5                                  -4.5              (-7.8, -1.0)              0.012

All parameters barring LV ejection fraction have been log-transformed and are therefore expressed as percentage change.

Model adjusted for age, age at menopause, ethnicity, height, weight, systolic blood pressure, diastolic blood pressure, smoking status, regular alcohol use, presence of raised cholesterol, presence of diabetes, Townsend deprivation index and income.

Results of interaction analyses using age\*MHT as an interaction term in our regression models are presented in [Table 4](#pone.0194015.t004){ref-type="table"} and [Fig 2](#pone.0194015.g002){ref-type="fig"}. Age significantly modified the association between MHT use and CMR parameters with smaller chambers observed with advancing tertiles of age: LV end-diastolic volume (47--60 years: β = 3.2%, 95% CI: -0.6% to 7.2%; 61--66 years: β = -2.9%, 95% CI: -5.8% to 0.2%; 67--77 years: β = -6.2%, 95% CI: -9.0% to -3.3%; p for interaction = 0.0005), LV end-systolic volume (47--60 years: β = 7.7%, 95% CI: 1.6% to 14.1%; 61--66 years: β = -3.1%, 95% CI: ---7.6% to 1.6%; 67--77 years: β = -5.9%, 95% CI: -10.1% to -1.4%; p for interaction = 0.001), LV stroke volume (47--60 years: β = 0.3%, 95% CI: -3.8% to 4.5%; 61--66 years: β = -2.6%, 95% CI: -5.9% to 0.8%; 67--77 years: β = -6.4%, 95% CI: -9.4% to -3.2%; p for interaction = 0.033), and LA maximal volume (47--60 years: β = 0.1%, 95% CI: -6.6% to 7.3%; 61--66 years: β = -1.2%, 95% CI: -6.6% to 4.6%; 67--77 years: β = -10.1%, 95% CI: -15.0% to -5.0%; p for interaction = 0.006).

![Interaction plots for age and MHT use.\
For every ten-year increment in age, there is a reduction in LV end-diastolic volume, LV end-systolic volume, LV stroke volume and LA maximal volume. The relationship between age and CMR outcomes is of greater magnitude amongst MHT users than that amongst non-users.](pone.0194015.g002){#pone.0194015.g002}

10.1371/journal.pone.0194015.t004

###### Effect modification analysis; interaction of MHT use with age.

![](pone.0194015.t004){#pone.0194015.t004g}

                                Tertile of age     MHT effect size   95% Confidence Interval   P value   P value for interaction with age
  ----------------------------- ------------------ ----------------- ------------------------- --------- ----------------------------------
  **LV end-diastolic volume**   1\) 47--60 years   3.2%              (-0.6, 7.2)               0.096     p = 0.0005
  2\) 61--66 years              -2.9%              (-5.8, 0.2)       0.064                               
  3\) 67--77 years              -6.2%              (-9.0, -3.3)      \<0.0001                            
  **LV end-systolic volume**    1\) 47--60 years   7.7%              (1.6, 14.1)               0.012     p = 0.001
  2\) 61--66 years              -3.1%              (-7.6, 1.6)       0.195                               
  3\) 67--77 years              -5.9%              (-10.1, -1.4)     0.010                               
  **LV stroke volume**          1\) 47--60 years   0.3%              (-3.8, 4.5)               0.896     p = 0.033
  2\) 61--66 years              -2.6%              (-5.9, 0.8)       0.128                               
  3\) 67--77 years              -6.4%              (-9.4, -3.2)      \<0.0001                            
  **LA maximal volume**         1\) 47--60 years   0.1%              (-6.6, 7.3)               0.974     p = 0.006
  2\) 61--66 years              -1.2%              (-6.6, 4.6)       0.688                               
  3\) 67--77 years              -10.1%             (-15.0, -5.0)     0.0002                              

Effect sizes presented following adjustment for: duration of MHT use fitted as tertiles, age at menopause, ethnicity, height, weight, systolic blood pressure, diastolic blood pressure, smoking status, regular alcohol use, presence of raised cholesterol, presence of diabetes, Townsend score and income.

Results from sensitivity analyses examining the difference between CMR parameters in MHT users ≥ 3 years and propensity-matched controls are presented in [Table 5](#pone.0194015.t005){ref-type="table"}. There were 429 matched participants in each group. As in multivariable regression models ([Table 3](#pone.0194015.t003){ref-type="table"}), LV end-diastolic volume (MHT users = 117.5 ml vs never users = 121.7 ml, mean difference = -3.2%, 95% CI: -5.5% to -0.9%; p = 0.007), LV stroke volume (MHT users = 70.9 ml vs never users = 73.8 ml, mean difference = -3.7%, 95% CI: -6.1% to -1.3%; p = 0.003) and LA maximal volume (MHT users = 56.8 ml vs never users = 59.4 ml, mean difference = -4.9%, 95% CI: -8.9% to -0.8%; p = 0.019) were significantly lower in MHT users ≥3 years. [S2 Table](#pone.0194015.s002){ref-type="supplementary-material"} details the balance between the co-variates both before and after propensity-matching.

10.1371/journal.pone.0194015.t005

###### Sensitivity analysis: Mean difference in CMR parameters by MHT users ≥ 3 years and propensity-matched controls.

![](pone.0194015.t005){#pone.0194015.t005g}

                                Mean (SD) in MHT users ≥3 years (n = 429)   Mean (SD) in propensity-matched controls (n = 429)   Mean difference (%)   95% confidence interval   P value
  ----------------------------- ------------------------------------------- ---------------------------------------------------- --------------------- ------------------------- ---------
  **LV end-diastolic volume**   117.5 (21.6)                                121.7 (19.9)                                         -3.2                  (-5.5, -0.9)              0.007
  **LV end-systolic volume**    45.6 (11.8)                                 47.0 (11.9)                                          -2.5                  (-5.8, 1.0)               0.157
  **LV stroke volume**          70.9 (14.2)                                 73.8 (12.7)                                          -3.7                  (-6.1, -1.3)              0.003
  **LV ejection fraction**      60.8 (6.1)                                  61.0 (6.1)                                           -0.4                  (-1.2, 0.5)               0.394
  **LV mass**                   70.9 (14.2)                                 71.6 (13.2)                                          -0.7                  (-3.2, 2.0)               0.601
  **LA maximal volume**         56.8 (17.0)                                 59.4 (17.3)                                          -4.9                  (-8.9, -0.8)              0.019

Propensity-matched controls are selected using the following variables: age, age at menopause, ethnicity, height, body mass index, systolic blood pressure, diastolic blood pressure, smoking status, regular alcohol use, presence of raised cholesterol and presence of diabetes, Townsend deprivation index and income.

Discussion {#sec013}
==========

In a population-based cohort of 1604 post-menopausal women free of known cardiovascular disease, the present study identified the following: firstly, LV end-diastolic volumes and LA maximal volumes were lower in women using MHT ≥ 3 years compared to those who had never used MHT after accounting for potential confounders. Secondly, MHT use significantly modified the relationship between advancing age and LV end-diastolic volume, LV end-systolic volume and LA maximal volume. Thirdly, timing of commencement of MHT in relation to the onset of menopause had no discernible impact of LV or LA volumes.

This study describes the relationship between MHT use and prognostically important cardiac phenotypes and indicates lower LV end-diastolic and LA maximal volumes in women who used MHT ≥ 3 years compared to those who never received treatment. Increases in LV volumes--LV dilatation--is associated with cardiac decompensation and poor prognosis in a range of cardiovascular diseases. Increases in end-diastolic volume and end-systolic volume have been demonstrated to be associated with an increased risk of heart failure in asymptomatic individuals \[[@pone.0194015.ref022]\] whilst reduction in LV volumes--indicative of reverse cardiac remodelling--is associated with favourable outcomes \[[@pone.0194015.ref023],[@pone.0194015.ref024]\]. Equivalently, LA enlargement, as determined by LA maximal volume, is a robust and independent predictor of incident cardiovascular events \[[@pone.0194015.ref025],[@pone.0194015.ref026]\] whilst reduction in LA volumes (reverse remodelling) is associated with lower mortality and risk of heart failure \[[@pone.0194015.ref027]\]. There was no significant difference in LV mass between MHT users ≥ 3 years and those who had never used MHT. LV mass is one of the most important cardiovascular imaging-derived phenotypes with increases in LV mass predicting a higher incidence of cardiovascular events and mortality \[[@pone.0194015.ref028]\].

This study demonstrates that use of MHT significantly impacts upon age-related reduction in LV and LA volumes. Recently published data detailing reference ranges for CMR imaging derived from a strictly healthy UK Biobank cohort has demonstrated that LV end-diastolic volume, end-systolic volume and LA maximal volume all decrease with advancing age \[[@pone.0194015.ref017]\], in keeping with findings from the never used MHT cohort. It is noteworthy, however, that use of MHT results in a much more marked rate of diminishment in LV and LA volumes, even after accounting for duration of MHT in addition to other confounders. Given that only 15% of women were using MHT at the time of CMR examination, it appears that this is an effect that persists, rather than being a contemporaneous result of being on treatment.

CMR is the most accurate and reproducible cardiac imaging modality and, when coupled with a large cohort size, permits detection of subclinical changes in cardiac structure and function. Whilst these subtle alterations may not result in any discernible impact to an individual at a single point in time, if they persist it is possible that they will eventually lead to prognostically relevant changes in cardiovascular outcomes. To our knowledge, this study is the first to explore the relationship between MHT use and subclinical changes in cardiac structure and function. Previous studies examining the impact of MHT on the cardiovascular system at the subclinical stage have focused on atherosclerotic burden as detected by cardiac computed tomography (CT). The most influential of these was a substudy of the Women's Health Initiative which reported the coronary artery calcified-plaque burden was lower in women assigned to MHT than in those assigned to placebo \[[@pone.0194015.ref029]\]. The more recent Early versus Late Intervention Trial with Estradiol (ELITE) study \[[@pone.0194015.ref030]\], designed specifically to investigate the "timing hypothesis" in relation to atherosclerosis progression in post-menopausal women, did not show any difference in plaque burden as assessed by cardiac CT in either early (\<6 years) or late (≥10 years) menopause when compared to placebo although the authors did state that their sample size may be insufficient to detect any difference.

Despite landmark randomised trials and systematic reviews \[[@pone.0194015.ref031]\] declaring that MHT does not provide any protective effects from cardiac events or mortality, this has been challenged by more recent studies examining both clinical end-points and surrogate markers of atherosclerosis progression. What is clear is that there remains significant confusion regarding MHT's benefit, or lack thereof, in relation to cardiovascular health. Discouragingly, it has been noted that it is "unlikely" that additional large, prospective trials will be performed investigating MHT's impact on cardiovascular disease due to existing controversy, fear of potential harm and the expense associated with longitudinal follow-up \[[@pone.0194015.ref032]\]. We hope that our utilisation of biomarkers provided by CMR in the context of a large-scale, population-based study such as UK Biobank has provided a useful and novel method of examining MHT's influence on the cardiovascular system.

This study used a large population-based cohort, with uniform assessment of exposures, covariates and outcomes. Importantly, there was no difference in socioeconomic status between the two groups; previous studies have highlighted that women prescribed MHT are of higher social class and educational attainment--and therefore, in general, healthier--than women who do not receive MHT, thereby confounding results \[[@pone.0194015.ref033],[@pone.0194015.ref034]\]. This is something that we have attempted to control for in this data. However, there are several limitations that should be considered in the interpretation of the findings. Firstly, the analysis was cross-sectional, thus causality cannot be inferred from the associations demonstrated. Secondly, it was not possible to explore longitudinal change in cardiac structure in relation to MHT use. Thirdly, all menopause and MHT data was self-reported. Finally, we were not able to provide data on type of MHT due to significant amount of missing data.

Conclusions {#sec014}
===========

In a large, population-based cohort of post-menopausal women free of cardiovascular disease, use of MHT is not associated with adverse, subclinical changes in cardiac structure and function. Indeed, we demonstrate significantly smaller LV and LA chamber volumes which have been linked to favourable cardiovascular outcomes in other settings. Our findings provide a novel way to examine the impact of MHT on the cardiovascular system; future work will focus upon linkage of MHT use and CMR parameters to cardiovascular outcome data.

Supporting information {#sec015}
======================

###### Effect of MHT use ≥ 3 years on CMR parameters in fully-adjusted models after multiple imputation of missing values.

Data was partially missing for 275/1604 (17%) of participants. Between those with missing and no missing data, the groups were similar for all co-variates other than BMI (25.8 kg/m^2^ vs. 26.8 kg/m^2^, p = 0.003) and systolic blood pressure (133 mmHg vs. 137 mmHg, p = 0.009) which were higher in those with missing data. After multiple imputation of missing values, the effect sizes are similar to those from complete case analysis with the same CMR parameters realising significance. The complete case analysis detailed in the main manuscript provides more conservative results.

(DOCX)

###### 

Click here for additional data file.

###### Co-variate balance before and after propensity-matching.

Propsensity matching was performed using "MatchIt" package in R. Optimal matching technique was used.

(DOCX)

###### 

Click here for additional data file.
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